• Adult patients from 18 to 70 years of age inclusive

• Systemic sclerosis according to 2013 ACR/EULAR classification criteria

• Limited or diffuse cutaneous subsets

• Systemic sclerosis disease duration within 6 years from first non-Raynaud's phenomenon manifestation at the time of signing the ICF

• Either HAQ-DI score ≥ 0.25 points or PtGA score ≥ 3 points

• mRSS \> 10 with early disease or rapid progression as defined by the protocol

• mRSS ≥ 15 with disease duration ≥ 18 months and active disease as defined by the protocol

• Stable background therapies can be used including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, mycophenolate sodium, mycophenolic acid, oral glucocorticoids or tacrolimus

• Women of childbearing potential with a negative urine pregnancy test

⁃ Uninvolved skin at injection sites